Next-Level Ocular Allergy Treatments

Name: Next-Level Ocular Allergy Treatments
Uploaded: 2022-07-13T04:00:00+00:00
Duration: 17 min 48 s
Description: Bobby Saenz, OD, MS, FAAO, and Mitch Ibach, OD, FAAO, discuss two cases that highlight next-generation of treatments for patients with allergic conjunctivi

Media formats available:

Details

Presenters

Overview
Bobby Saenz, OD, MS, FAAO, and Mitch Ibach, OD, FAAO, discuss two cases that highlight next-generation of treatments for patients with allergic conjunctivitis.
Supported by an unrestricted educational grant from Ocular Therapeutix.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Differentiate between the various types and stages of ocular allergies based on presentation
- Create individualized management options for ocular allergy based on disease severity, patient factors, and associated risks and benefits
- Describe the limitations of current treatment options for ocular allergy
- Evaluate new management options for ocular allergy
Participation Method
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Faculty and Disclosures
Mitch Ibach, OD, FAAO
Cataract, Cornea, Refractive, and Glaucoma Surgery Specialist
Vance Thompson Vision
Sioux Falls, SD

Bobby Saenz, OD, MS, FAAO
Clinic Director
Parkhurst NuVision
San Antonio, TX

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Mitch Ibach, OD, FAAO, has had a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Aerie Pharmaceuticals, Alcon, Allergan, Avellino, Bausch + Lomb, Dompé, Gauch Health, Glaukos, Heru, Kala Pharmaceuticals, Ocular Therapeutix, Oyster Point, and Sight Sciences. Grant/Research Support: Ocular Therapeutix. Speakers’ Bureau: Aerie Pharmaceuticals, Dompé, Glaukos, Heru, Ocular Therapeutix, Oyster Point, Sight Sciences, and Sun Pharmaceutical Industries. Stock/Shareholder: Equinox.
Bobby Saenz, OD, MS, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, LENSAR, Oyster Point, and Quidel. Grants/Research Support: Novartis, Ocular Therapeutix, Sight Sciences, and Sun Pharmaceuticals. Speaker's Bureau: Allergan, Biotissue, Carl Zeiss Meditec, Glaukos, Johnson & Johnson Vision, and Lumenis.
The Evolve staff and planners have no financial relationships with ineligible companies.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Ocular Therapeutix.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 07/13/2022